Nat Med:肿瘤免疫学的毒副作用

2017-05-09 zhangfan MedSci原创

肿瘤免疫的未来发展方向将集中于减少免疫毒性,普及免疫治疗应用适应性展开

免疫肿瘤学是近年来抗肿瘤领域取得的标志性胜利,是第一个广泛有效的抗癌症转移策略。免疫肿瘤学的兴起不但要求临床医生将化疗,放疗和靶向小分子抗肿瘤药物与抗肿瘤免疫疗法充分结合,而且要了解免疫治疗的局限性和毒性。

最初认为,免疫治疗较其他癌症治疗方法毒性相对较小-也的确如此。随着肿瘤免疫治疗越来越普及,特别是成为一二线治疗方法后,免疫毒性和自身免疫的出现可能成为免疫肿瘤学的致命要害。但研究发现,部分的免疫毒性预示着病人好转,相关的自身免疫诱导机制十分复杂。

肿瘤免疫的未来发展方向将集中于减少免疫毒性,普及免疫治疗应用适应性展开。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2078788, encodeId=cb8820e878832, content=<a href='/topic/show?id=6dbc635680d' target=_blank style='color:#2F92EE;'>#毒副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63568, encryptionId=6dbc635680d, topicName=毒副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 28 19:59:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824235, encodeId=c1df1824235da, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Jan 07 19:59:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882010, encodeId=6f1a188201007, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jun 14 04:59:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889409, encodeId=e433188940969, content=<a href='/topic/show?id=f9fa290030a' target=_blank style='color:#2F92EE;'>#免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29003, encryptionId=f9fa290030a, topicName=免疫学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Nov 11 10:59:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197466, encodeId=6b3a19e46660, content=每天学点新知识是种轻松途径, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat May 13 08:32:31 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196452, encodeId=41dd19645263, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。给点个赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu May 11 06:44:21 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607495, encodeId=d45a160e495c9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu May 11 04:59:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618190, encodeId=c7881618190c8, content=<a href='/topic/show?id=9e0d8281054' target=_blank style='color:#2F92EE;'>#肿瘤免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82810, encryptionId=9e0d8281054, topicName=肿瘤免疫学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8dd19859628, createdName=12498cbcm06(暂无昵称), createdTime=Thu May 11 04:59:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196257, encodeId=af0819625e75, content=毒副作用难免会有, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed May 10 15:11:01 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196201, encodeId=0f2619620131, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erHVQYic6jiaiaqTkfBFOGsLLCna8856OQVlTiam04gWF9VicCxBVWUMX633C5v0U2Lc6cdicOnZvyGSu9g/132, createdBy=73bd2007843, createdName=李跃先, createdTime=Wed May 10 12:14:34 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2078788, encodeId=cb8820e878832, content=<a href='/topic/show?id=6dbc635680d' target=_blank style='color:#2F92EE;'>#毒副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63568, encryptionId=6dbc635680d, topicName=毒副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 28 19:59:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824235, encodeId=c1df1824235da, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Jan 07 19:59:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882010, encodeId=6f1a188201007, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jun 14 04:59:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889409, encodeId=e433188940969, content=<a href='/topic/show?id=f9fa290030a' target=_blank style='color:#2F92EE;'>#免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29003, encryptionId=f9fa290030a, topicName=免疫学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Nov 11 10:59:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197466, encodeId=6b3a19e46660, content=每天学点新知识是种轻松途径, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat May 13 08:32:31 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196452, encodeId=41dd19645263, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。给点个赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu May 11 06:44:21 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607495, encodeId=d45a160e495c9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu May 11 04:59:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618190, encodeId=c7881618190c8, content=<a href='/topic/show?id=9e0d8281054' target=_blank style='color:#2F92EE;'>#肿瘤免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82810, encryptionId=9e0d8281054, topicName=肿瘤免疫学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8dd19859628, createdName=12498cbcm06(暂无昵称), createdTime=Thu May 11 04:59:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196257, encodeId=af0819625e75, content=毒副作用难免会有, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed May 10 15:11:01 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196201, encodeId=0f2619620131, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erHVQYic6jiaiaqTkfBFOGsLLCna8856OQVlTiam04gWF9VicCxBVWUMX633C5v0U2Lc6cdicOnZvyGSu9g/132, createdBy=73bd2007843, createdName=李跃先, createdTime=Wed May 10 12:14:34 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2078788, encodeId=cb8820e878832, content=<a href='/topic/show?id=6dbc635680d' target=_blank style='color:#2F92EE;'>#毒副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63568, encryptionId=6dbc635680d, topicName=毒副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 28 19:59:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824235, encodeId=c1df1824235da, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Jan 07 19:59:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882010, encodeId=6f1a188201007, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jun 14 04:59:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889409, encodeId=e433188940969, content=<a href='/topic/show?id=f9fa290030a' target=_blank style='color:#2F92EE;'>#免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29003, encryptionId=f9fa290030a, topicName=免疫学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Nov 11 10:59:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197466, encodeId=6b3a19e46660, content=每天学点新知识是种轻松途径, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat May 13 08:32:31 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196452, encodeId=41dd19645263, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。给点个赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu May 11 06:44:21 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607495, encodeId=d45a160e495c9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu May 11 04:59:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618190, encodeId=c7881618190c8, content=<a href='/topic/show?id=9e0d8281054' target=_blank style='color:#2F92EE;'>#肿瘤免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82810, encryptionId=9e0d8281054, topicName=肿瘤免疫学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8dd19859628, createdName=12498cbcm06(暂无昵称), createdTime=Thu May 11 04:59:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196257, encodeId=af0819625e75, content=毒副作用难免会有, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed May 10 15:11:01 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196201, encodeId=0f2619620131, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erHVQYic6jiaiaqTkfBFOGsLLCna8856OQVlTiam04gWF9VicCxBVWUMX633C5v0U2Lc6cdicOnZvyGSu9g/132, createdBy=73bd2007843, createdName=李跃先, createdTime=Wed May 10 12:14:34 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
    2017-06-14 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=2078788, encodeId=cb8820e878832, content=<a href='/topic/show?id=6dbc635680d' target=_blank style='color:#2F92EE;'>#毒副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63568, encryptionId=6dbc635680d, topicName=毒副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 28 19:59:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824235, encodeId=c1df1824235da, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Jan 07 19:59:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882010, encodeId=6f1a188201007, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jun 14 04:59:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889409, encodeId=e433188940969, content=<a href='/topic/show?id=f9fa290030a' target=_blank style='color:#2F92EE;'>#免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29003, encryptionId=f9fa290030a, topicName=免疫学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Nov 11 10:59:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197466, encodeId=6b3a19e46660, content=每天学点新知识是种轻松途径, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat May 13 08:32:31 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196452, encodeId=41dd19645263, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。给点个赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu May 11 06:44:21 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607495, encodeId=d45a160e495c9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu May 11 04:59:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618190, encodeId=c7881618190c8, content=<a href='/topic/show?id=9e0d8281054' target=_blank style='color:#2F92EE;'>#肿瘤免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82810, encryptionId=9e0d8281054, topicName=肿瘤免疫学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8dd19859628, createdName=12498cbcm06(暂无昵称), createdTime=Thu May 11 04:59:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196257, encodeId=af0819625e75, content=毒副作用难免会有, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed May 10 15:11:01 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196201, encodeId=0f2619620131, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erHVQYic6jiaiaqTkfBFOGsLLCna8856OQVlTiam04gWF9VicCxBVWUMX633C5v0U2Lc6cdicOnZvyGSu9g/132, createdBy=73bd2007843, createdName=李跃先, createdTime=Wed May 10 12:14:34 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2078788, encodeId=cb8820e878832, content=<a href='/topic/show?id=6dbc635680d' target=_blank style='color:#2F92EE;'>#毒副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63568, encryptionId=6dbc635680d, topicName=毒副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 28 19:59:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824235, encodeId=c1df1824235da, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Jan 07 19:59:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882010, encodeId=6f1a188201007, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jun 14 04:59:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889409, encodeId=e433188940969, content=<a href='/topic/show?id=f9fa290030a' target=_blank style='color:#2F92EE;'>#免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29003, encryptionId=f9fa290030a, topicName=免疫学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Nov 11 10:59:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197466, encodeId=6b3a19e46660, content=每天学点新知识是种轻松途径, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat May 13 08:32:31 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196452, encodeId=41dd19645263, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。给点个赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu May 11 06:44:21 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607495, encodeId=d45a160e495c9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu May 11 04:59:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618190, encodeId=c7881618190c8, content=<a href='/topic/show?id=9e0d8281054' target=_blank style='color:#2F92EE;'>#肿瘤免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82810, encryptionId=9e0d8281054, topicName=肿瘤免疫学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8dd19859628, createdName=12498cbcm06(暂无昵称), createdTime=Thu May 11 04:59:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196257, encodeId=af0819625e75, content=毒副作用难免会有, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed May 10 15:11:01 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196201, encodeId=0f2619620131, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erHVQYic6jiaiaqTkfBFOGsLLCna8856OQVlTiam04gWF9VicCxBVWUMX633C5v0U2Lc6cdicOnZvyGSu9g/132, createdBy=73bd2007843, createdName=李跃先, createdTime=Wed May 10 12:14:34 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
    2017-05-13 日月生辉

    每天学点新知识是种轻松途径

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2078788, encodeId=cb8820e878832, content=<a href='/topic/show?id=6dbc635680d' target=_blank style='color:#2F92EE;'>#毒副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63568, encryptionId=6dbc635680d, topicName=毒副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 28 19:59:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824235, encodeId=c1df1824235da, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Jan 07 19:59:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882010, encodeId=6f1a188201007, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jun 14 04:59:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889409, encodeId=e433188940969, content=<a href='/topic/show?id=f9fa290030a' target=_blank style='color:#2F92EE;'>#免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29003, encryptionId=f9fa290030a, topicName=免疫学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Nov 11 10:59:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197466, encodeId=6b3a19e46660, content=每天学点新知识是种轻松途径, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat May 13 08:32:31 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196452, encodeId=41dd19645263, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。给点个赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu May 11 06:44:21 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607495, encodeId=d45a160e495c9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu May 11 04:59:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618190, encodeId=c7881618190c8, content=<a href='/topic/show?id=9e0d8281054' target=_blank style='color:#2F92EE;'>#肿瘤免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82810, encryptionId=9e0d8281054, topicName=肿瘤免疫学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8dd19859628, createdName=12498cbcm06(暂无昵称), createdTime=Thu May 11 04:59:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196257, encodeId=af0819625e75, content=毒副作用难免会有, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed May 10 15:11:01 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196201, encodeId=0f2619620131, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erHVQYic6jiaiaqTkfBFOGsLLCna8856OQVlTiam04gWF9VicCxBVWUMX633C5v0U2Lc6cdicOnZvyGSu9g/132, createdBy=73bd2007843, createdName=李跃先, createdTime=Wed May 10 12:14:34 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
    2017-05-11 ylzr123

    不错的方式,努力学习,刻苦专研,不断总结出来新经验。给点个赞!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2078788, encodeId=cb8820e878832, content=<a href='/topic/show?id=6dbc635680d' target=_blank style='color:#2F92EE;'>#毒副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63568, encryptionId=6dbc635680d, topicName=毒副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 28 19:59:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824235, encodeId=c1df1824235da, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Jan 07 19:59:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882010, encodeId=6f1a188201007, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jun 14 04:59:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889409, encodeId=e433188940969, content=<a href='/topic/show?id=f9fa290030a' target=_blank style='color:#2F92EE;'>#免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29003, encryptionId=f9fa290030a, topicName=免疫学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Nov 11 10:59:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197466, encodeId=6b3a19e46660, content=每天学点新知识是种轻松途径, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat May 13 08:32:31 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196452, encodeId=41dd19645263, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。给点个赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu May 11 06:44:21 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607495, encodeId=d45a160e495c9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu May 11 04:59:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618190, encodeId=c7881618190c8, content=<a href='/topic/show?id=9e0d8281054' target=_blank style='color:#2F92EE;'>#肿瘤免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82810, encryptionId=9e0d8281054, topicName=肿瘤免疫学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8dd19859628, createdName=12498cbcm06(暂无昵称), createdTime=Thu May 11 04:59:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196257, encodeId=af0819625e75, content=毒副作用难免会有, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed May 10 15:11:01 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196201, encodeId=0f2619620131, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erHVQYic6jiaiaqTkfBFOGsLLCna8856OQVlTiam04gWF9VicCxBVWUMX633C5v0U2Lc6cdicOnZvyGSu9g/132, createdBy=73bd2007843, createdName=李跃先, createdTime=Wed May 10 12:14:34 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2078788, encodeId=cb8820e878832, content=<a href='/topic/show?id=6dbc635680d' target=_blank style='color:#2F92EE;'>#毒副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63568, encryptionId=6dbc635680d, topicName=毒副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 28 19:59:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824235, encodeId=c1df1824235da, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Jan 07 19:59:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882010, encodeId=6f1a188201007, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jun 14 04:59:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889409, encodeId=e433188940969, content=<a href='/topic/show?id=f9fa290030a' target=_blank style='color:#2F92EE;'>#免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29003, encryptionId=f9fa290030a, topicName=免疫学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Nov 11 10:59:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197466, encodeId=6b3a19e46660, content=每天学点新知识是种轻松途径, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat May 13 08:32:31 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196452, encodeId=41dd19645263, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。给点个赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu May 11 06:44:21 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607495, encodeId=d45a160e495c9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu May 11 04:59:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618190, encodeId=c7881618190c8, content=<a href='/topic/show?id=9e0d8281054' target=_blank style='color:#2F92EE;'>#肿瘤免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82810, encryptionId=9e0d8281054, topicName=肿瘤免疫学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8dd19859628, createdName=12498cbcm06(暂无昵称), createdTime=Thu May 11 04:59:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196257, encodeId=af0819625e75, content=毒副作用难免会有, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed May 10 15:11:01 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196201, encodeId=0f2619620131, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erHVQYic6jiaiaqTkfBFOGsLLCna8856OQVlTiam04gWF9VicCxBVWUMX633C5v0U2Lc6cdicOnZvyGSu9g/132, createdBy=73bd2007843, createdName=李跃先, createdTime=Wed May 10 12:14:34 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=2078788, encodeId=cb8820e878832, content=<a href='/topic/show?id=6dbc635680d' target=_blank style='color:#2F92EE;'>#毒副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63568, encryptionId=6dbc635680d, topicName=毒副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 28 19:59:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824235, encodeId=c1df1824235da, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Jan 07 19:59:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882010, encodeId=6f1a188201007, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jun 14 04:59:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889409, encodeId=e433188940969, content=<a href='/topic/show?id=f9fa290030a' target=_blank style='color:#2F92EE;'>#免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29003, encryptionId=f9fa290030a, topicName=免疫学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Nov 11 10:59:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197466, encodeId=6b3a19e46660, content=每天学点新知识是种轻松途径, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat May 13 08:32:31 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196452, encodeId=41dd19645263, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。给点个赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu May 11 06:44:21 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607495, encodeId=d45a160e495c9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu May 11 04:59:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618190, encodeId=c7881618190c8, content=<a href='/topic/show?id=9e0d8281054' target=_blank style='color:#2F92EE;'>#肿瘤免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82810, encryptionId=9e0d8281054, topicName=肿瘤免疫学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8dd19859628, createdName=12498cbcm06(暂无昵称), createdTime=Thu May 11 04:59:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196257, encodeId=af0819625e75, content=毒副作用难免会有, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed May 10 15:11:01 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196201, encodeId=0f2619620131, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erHVQYic6jiaiaqTkfBFOGsLLCna8856OQVlTiam04gWF9VicCxBVWUMX633C5v0U2Lc6cdicOnZvyGSu9g/132, createdBy=73bd2007843, createdName=李跃先, createdTime=Wed May 10 12:14:34 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
    2017-05-10 1e1b8538m79(暂无匿称)

    毒副作用难免会有

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2078788, encodeId=cb8820e878832, content=<a href='/topic/show?id=6dbc635680d' target=_blank style='color:#2F92EE;'>#毒副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63568, encryptionId=6dbc635680d, topicName=毒副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Thu Dec 28 19:59:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1824235, encodeId=c1df1824235da, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Jan 07 19:59:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882010, encodeId=6f1a188201007, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Jun 14 04:59:00 CST 2017, time=2017-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1889409, encodeId=e433188940969, content=<a href='/topic/show?id=f9fa290030a' target=_blank style='color:#2F92EE;'>#免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29003, encryptionId=f9fa290030a, topicName=免疫学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Sat Nov 11 10:59:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=197466, encodeId=6b3a19e46660, content=每天学点新知识是种轻松途径, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib260FNcic8ThYQJjaU2fLIb1yNqibkbdJs7gVIDr9xJyYeiapArSMjn3W61bPJtpIazSdAxRaFEOKYgfQjX4achN2d/0, createdBy=68472058812, createdName=日月生辉, createdTime=Sat May 13 08:32:31 CST 2017, time=2017-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196452, encodeId=41dd19645263, content=不错的方式,努力学习,刻苦专研,不断总结出来新经验。给点个赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu May 11 06:44:21 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607495, encodeId=d45a160e495c9, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu May 11 04:59:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618190, encodeId=c7881618190c8, content=<a href='/topic/show?id=9e0d8281054' target=_blank style='color:#2F92EE;'>#肿瘤免疫学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82810, encryptionId=9e0d8281054, topicName=肿瘤免疫学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8dd19859628, createdName=12498cbcm06(暂无昵称), createdTime=Thu May 11 04:59:00 CST 2017, time=2017-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196257, encodeId=af0819625e75, content=毒副作用难免会有, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Wed May 10 15:11:01 CST 2017, time=2017-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=196201, encodeId=0f2619620131, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erHVQYic6jiaiaqTkfBFOGsLLCna8856OQVlTiam04gWF9VicCxBVWUMX633C5v0U2Lc6cdicOnZvyGSu9g/132, createdBy=73bd2007843, createdName=李跃先, createdTime=Wed May 10 12:14:34 CST 2017, time=2017-05-10, status=1, ipAttribution=)]
    2017-05-10 李跃先

    学习

    0

相关资讯

PNAS:上海交大研究人员揭示mTOR抑制剂对DNMT3A突变相关白血病的治疗作用

来自上海交通大学医学院,瑞金医院等处的研究人员发表了题为“Conditional knockin of Dnmt3a R878H initiates acute myeloid leukemia with mTOR pathway involvement”的文章,分析了DNMT3A最常见的突变形式,发现mTOR通路激活是白血病致病机理中的关键参与者,并且也揭示出了mTOR抑制剂对DNMT3A突变相

Sci Rep:近代物理所揭示miR-449a增强肿瘤细胞辐射敏感性的新机制

中国科学院近代物理研究所辐射医学研究室科研人员利用兰州重离子加速器国家实验室提供的实验条件,研究miR-449a在肿瘤细胞应答电离辐射中的作用机理,获得新发现。microRNA(miRNA)是一类在细胞核内表达的非编码小RNA,主要通过在细胞质中与mRNA的3’UTR上的靶点结合,通过降低mRNA的稳定性降解靶mRNA或阻遏mRNA的翻译,从而调控转录后水平基因表达,进而影响多个信号传导通路。mi

治疗帕金森氏病药物苄丝肼意外发现能靶向抗肿瘤

来自华中科技大学和沈阳药科大学的研究人员发表了“Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2”的文章,他们意外地发现抗帕金森综合症药物苄丝肼能够靶向肿瘤代谢的关键酶己糖激酶2 (hexokinase 2, HK2),而在体内外发挥抗癌活性。传统认为,苄丝肼为

天津免费筛查4类恶性肿瘤

天津市2017年常见恶性肿瘤早诊早治项目、天津市河西区肿瘤防治示范区项目近日在天津市肿瘤医院启动。5月~8月,两项目将免费为5.8万名40岁~74岁常住居民开展肺癌、乳腺癌、肝癌和胃癌筛查,以期探索形成符合天津实际的常见恶性肿瘤精准筛查模式。

Nat Med:晚期肿瘤基因组突变特征研究

肿瘤分子分析是精密肿瘤学的基本组成部分,能够识别肿瘤细胞基因组改变实现靶向治疗。

Int J Epidemiol:多吃水果能预防癌症及心血管疾病

新鲜水果的食用有助于减少心血管疾病的患病风险这一说法,目前仍缺少先关的证据。发表在Int J Epidemiol杂志上的一篇文章对其进行了相关的研究。该研究者于2004年8月份,在中国不同区域招募了年龄在30-79岁之间的成人约50万人,对其日常水果食用情况进行了访谈式调查问卷的调研,并从死亡登记数据库获得死亡率的相关数据。在462342名明确诊断不伴有COPD疾病的患者当中,17894名患者在随